A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this clinical trial is to learn if the TheraBionic P1 device given to patients with advanced or metastatic HR positive, HER2 negative breast cancer who have progressed on standard of care options can affect patients survival. The main questions it aims to answer are: * will the TheraBionic P1 device affect progression free and overall survival in advanced or metastatic HR positive, HER2 negative breast cancer * the long term safety and tolerability of the TheraBionic P1 device * assessment of how the disease responded to the TheraBionic P1 device
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Zaawansowany rak piersi, który nie może być operacyjnie usunięty, lub rak z przerzutami, wrażliwy na hormony, bez nadmiaru receptora HER2
- •Wcześniejsze leczenie co najmniej jedną terapią hormonalną z inhibitorem CDK4/6 oraz co najmniej jedną chemioterapią lub innymi lekami biologicznymi
- •Kobieta w wieku co najmniej 22 lat, zdolna do podpisania zgody na uczestnictwo
- •Przewidywana długość życia co najmniej 3 miesiące
- •Ogólny stan zdrowia oceniony na 0-2 punkty w skali ECOG
- •Jeśli jest w wieku rozrodczym: zobowiązanie do uniknięcia ciąży od rozpoczęcia leczenia przez co najmniej 30 dni po ostatniej sesji
Simplified criteria — AI translation
Trial details
- Minimum age
- 22 Years
- Last updated (source)
- August 26, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (8)
Karmanos Cancer Institute at McLaren Bay Region
Bay City, United States
Karmanos Cancer Institute at McLaren Clarkston
Clarkston, United States
Karmanos Cancer Institute
Detroit, United States
Karmanos Cancer Institute at McLaren Flint
Flint, United States
Karmanos Cancer Institute at McLaren Lapeer Region
Lapeer, United States
Karmanos Cancer Institute at McLaren Macomb
Mount Clemens, United States
Karmanos Cancer Institute at McLaren Northern
Petoskey, United States
Karmanos Cancer Institute at McLaren Port Huron
Port Huron, United States
Trial contact
Hadeel Assad, M.D.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/27/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.